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Abstract
Background: Early neurological deterioration (END) is common after stroke. Prediction could identify patients
requiring additional monitoring and intervention. Purines, breakdown products of adenosine triphosphate which
accumulate during acute hypoxia, may reflect the subclinical presence of vulnerable tissue. We considered whether
whole blood purine concentration (WBPC) measurements during acute stroke were associated with subsequent END.
Methods: Patients within 4.5 h of stroke onset underwent point-of-care finger-prick measurement of WBPC and
blinded assessment of symptom severity using the National Institutes of Health Stroke Scale (NIHSS). END was defined
as an NIHSS increase ≥2 points at 24–36 h compared to baseline.
Results: 15/152 (9.8%) patients experienced END with a median [IQR] NIHSS increase of 4 [2–7] points. There were no
strong associations between END and baseline NIHSS, clinical stroke subtype, thrombolytic therapy, physiological
characteristics or time to assay. The median [IQR] WBPC concentration (uM) was higher before the occurrence of END
but without statistical significance (7.21 [4.77–10.65] versus 4.83 [3.00–9.02]; p = 0.1). Above a WBPC threshold of 6.
05uM, the risk of END was significantly greater (odds ratio 3.7 (95% CI 1.1–12.4); p = 0.03).
Conclusion: Although the study lacked statistical power, early WBPC measurement could be a convenient biomarker
for identifying acute stroke patients at risk of END, but further evaluation is required.
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Background
Early neurological deterioration (END) describes wors-
ening of symptoms during the initial period following
stroke onset and is associated with poorer outcomes.
Incidence ranges from 2.2 to 37.5% depending upon the
choice of severity threshold and the time elapsed
between assessments [1–4]. A typical definition is an
increase of at least two points in National Institutes of
Health Stroke Score (NIHSS) at 24–48 h following
admission [1, 2]. Secondary causes are common (e.g.
sepsis), but END also reflects progressive failure of
penumbral tissue surrounding an ischaemic core or
compressive haematoma [3–5], as well as local haemo-
dynamic disturbances, extension of thrombosis, excito-
toxicity, and inflammation, which may be greater
influences upon the progression of lacunar infarction
[6]. Although advanced imaging techniques such as MR
and CT perfusion can demonstrate the volume of threat-
ened ischaemic tissue during acute stroke, this is not
quantifiable using standard brain imaging and advanced
techniques are not routinely available [5]. Convenient
prediction of END risk during initial clinical review
could aid identification of patients requiring additional
imaging, monitoring and/or early intervention.
Purines are nitrogen-containing compounds with a
short half-life which are released by breakdown of ad-
enosine triphosphate (ATP) and consumed again during
oxidative phosphorylation. Using a novel biosensor [7] to
quantify purines (adenosine, inosine and hypoxanthine), it
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has been demonstrated that carotid clamping during
endarterectomy without general anaesthetic results in
rapid elevation of the whole blood purine concentra-
tion (WBPC) from a baseline mean of 2.4 μM (95%
CI 1.3–4.0) to 6.7 μM (4.7–11.5), quickly returning to
1.9 μM (1.3–4.0) following clamp removal, without
neurological sequelae [8]. In the context of acute
stroke, WBPC may therefore be a responsive bio-
marker which rises not only in proportion to the
extent of clinically symptomatic hypo-perfused tissue,
but also according to the volume of subclinical
penumbra prior to its eventual re-oxygenation or
infarction. Development of the bio-sensor into a rapid
point-of-care test provided the opportunity to perform
a double-blind observational cohort study exploring
whether early WBPC measurement was associated
with subsequent END amongst patients with very
recent stroke symptoms.
Methods
Adults within 4.5 h of stroke symptom onset at 4
hospitals underwent point-of-care capillary sampling of
WBPC (SMARTChip assay; Sarissa Biomedical Ltd.,
Coventry, UK), clinical assessment (physiological obser-
vations; NIHSS) and CT brain imaging [9]. There was
no restriction on the type of symptoms, but NIHSS was
always > 0 at the time of sampling. Patients receiving
chemotherapy and acute gout treatment were excluded.
Stroke diagnosis and clinical subgroup using the
Oxford Community Stroke Project classification [10]
were confirmed by a local specialist following clinically
appropriate investigations, with additional adjudication
by at least one study investigator. Patients with sub-
arachnoid haemorrhage were excluded. The WBPC
reading was concealed from clinical assessors and per-
formed before any emergency medical treatment. All
patients receiving intravenous thrombolysis underwent
repeat brain imaging at 24 h. END was defined as an
increase ≥2 points between the first NIHSS and a second
assessment 24–36 h later.
Statistical comparison was made using Fisher’s Exact
Test for categorical data and the Mann Whitney U Test
for continuous variables due to the small sample size
and data distribution. Independent samples T-Test was
also applied to the WBPC values. Spearman’s rho exam-
ined correlation between variables. The utility of WBPC
as a biomarker for END was assessed by the area under
the curve (AUC) of the resulting receiver operating
characteristic (ROC) plot. Ethics approval was granted
by the National Research Ethics Service in England
(reference 16/WM/0164). All participants or their per-
sonal consultee gave informed consent consistent with
the principles of the Declaration of Helsinki.
Results
One hundred fifty-two patients were enrolled: 66 ischae-
mic stroke who did not receive intravenous thrombolysis
(ISNT), 61 ischaemic stroke receiving intravenous
thrombolysis (IST) and 25 intracerebral haemorrhage
(ICH). No patients received intra-arterial treatment. For
9 of 66 ISNT cases, the NIHSS at 24 h was zero and the
discharge diagnosis was transient ischaemic attack
(TIA). Early neurological deterioration occurred in 15
(9.8%) cases: 4 ISNT, 5 IST (none experienced haemor-
rhage on repeat brain imaging) and 6 ICH (1 requiring
craniotomy). Their median NIHSS increase was 4 (IQR
2–7) points. Apart from a small difference in oxygen
saturations favouring the END group, characteristics
were similar between groups (Table 1).
Baseline NIHSS was higher amongst the END group,
but this was not statistically significant (p = 0.26), and no
correlation was found between baseline NIHSS and
WBPC overall (Spearman’s rho = − 0.126; p = 0.313). No
significant differences were observed in the distribution
of clinical subgroups, including lacunar stroke.
Overall, WBPC was higher for the END group, but
this did not reach statistical significance. However, above
an optimal ROC threshold of 6.05 μM for WBPC, the
risk of END was significantly greater (odds ratio 3.7
(95% CI 1.1–12.4); p = 0.03). The ROC AUC for predic-
tion of END using a WBPC threshold of 6.05 μM was
0.63 (95% CI: 0.49–0.77).
Figure 1 shows the distribution of individual WBPC
measures according to each clinical diagnostic group
+/− END at a threshold of 6.05 μM. There were no
statistically significant WBPC differences between IST,
ISNT and ICH groups.
Discussion
Elevated WBPC during the first 4.5 h after stroke onset
was weakly associated with a greater risk of END at 24–
36 h. Although the association did not reach statistical
significance due to the size of the END group and the
mixed cohort characteristics, this remains an interesting
preliminary finding. As measurements occurred before
the typical timing of secondary causes such as sepsis,
and there were no major physiological differences
between groups on admission, early WBPC elevation
may indicate the subclinical presence of vulnerable
tissue. However, the moderate size of the AUC reflects
the preliminary nature of this study, and it would be ne-
cessary to undertake an adequately powered diagnostic
accuracy trial, which actively seeks multiple causes for
END over a longer interval, to be confident that WBPC
is a biomarker capable of informing early clinical deci-
sions about the intensity of monitoring and thresholds
for additional treatment.
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A maximum symptom duration of 4.5 h was chosen to
reflect the time window used by most clinical services to
trigger a standard emergency response for suspected
stroke, thereby ensuring that study results were directly
relevant to the largest and most important patient popu-
lation. In addition, extension of the sampling time
beyond 4.5 h would have demanded a larger overall
number of participants to detect any relationship be-
tween WBPC and END as the probability of viable
penumbral tissue would be reduced, whilst risks would
increase for the occurrence of other conditions poten-
tially affecting WBPC results (e.g. sepsis from early
aspiration pneumonia).
It is important to acknowledge that the END group
displayed greater initial stroke severity, which could
partly explain their increased risk of deterioration (e.g.
due to cerebral oedema). However, NIHSS comparison
with the nEND group was not statistically significant,
and no relationship was found between baseline NIHSS
and WBPC values overall. The latter observation may
reflect a cellular mechanism whereby tissue which has
become irreversibly damaged will cease ATP metabolism
and hence purine production, whereas hypoxic areas at
risk will consume ATP but without replenishment,
thereby elevating WBPC until perfusion is restored or
cell death occurs. A similar observation was previously
described during temporary carotid clamping, where the
WBPC rose above the current END threshold to a mean
of 6.7 μM, but returned to baseline levels without any
neurological consequences when perfusion was restored
[8]. A future study of serial measurements amongst
patients with different baseline NIHSS +/− thrombolysis
(e.g. every 6 h for 48 h) would assist with understanding
the dynamic profile of WBPC in relation to the evolu-
tion of stroke, and provide greater confidence that there
is a single threshold which reliably indicates ongoing
penumbral ischaemia rather than irreversible tissue
injury.
As this study was an initial exploration of the relation-
ship between WBPC and END, it was not designed to
specifically consider mechanisms for deterioration in
different clinical subgroups e.g. small versus large vessel
stroke, although none were evident. Failure of ATP
production is likely to be a common end-point for all
mechanisms leading to END, and no clear association
might be expected with WBPC elevation other than
to reflect the rate at which tissue injury occurs. How-
ever, as previously described, the frequency of END
was higher amongst the ICH than the IS group (6/25
versus 9/127 cases) [1, 4, 11]. Since clinical trial
evidence has confirmed a relationship between high
blood pressure, haematoma expansion and neurological
Table 1 Characteristics and outcomes with and without early neurological deterioration
non-END (n = 137) END (n = 15) p-value
Female, n (%) 70 (51%) 9 (60%) 0.59
Age (years) 76.0 (65.0–82.0) 79.0 (68.5–86.0) 0.42
Systolic blood pressure (mmHg) 158 (138–191) 174 (138–183) 0.82
Diastolic blood pressure (mmHg) 87 (75–96) 81 (74–92) 0.32
Heart rate (per minute) 83 (72–92) 76 (60–91) 0.27
Respirations (per minute) 17 (16–18) 16 (15–18) 0.89
Temperature (°C) 36.4 (36.1–36.7) 36.5 (36.4–36.8) 0.43
Oxygen saturations (%) 96 (95–98) 97 (96–99) 0.06
Clinical subgroup
LAC ischaemia/haemorrhage (subtotal %) 31/6 (27%) 2/2 (27%) 0.98
PAC ischaemia/haemorrhage (subtotal %) 39/5 (32%) 4/0 (27%) 0.67
TAC ischaemia/haemorrhage (subtotal %) 31/6 (27%) 3/4 (46%) 0.11
POC ischaemia/haemorrhage (subtotal %) 8/2 (7%) 0/0 (0%) 0.28
Transient ischaemic attacka 9 (7%) – –
Intravenous thrombolysis treatment (%) 56 (41%) 5 (33%) 0.59
Baseline NIHSS 7 (4–14) 13 (6–17) 0.26
24-36 h NIHSS 4 (1–10.25) 18 (13–25) < 0.01
Minutes from onset to assay 133 (96–180) 104 (73–146) 0.15
Whole blood purine concentration (μM) 4.83 (3.00–9.02) 7.21 (4.77–10.65) 0.10
Mean [SD] whole blood purine concentration (μM) 7.65 [7.67] 11.3 [11.60] 0.26
aTransient ischaemic attack cannot co-exist with END. Variables are median (IQR) unless otherwise stated; END early neurological deterioration, NIHSS National
Institutes of Health Stroke Scale, LAC lacunar circulation, PAC partial anterior circulation, TAC total anterior circulation, POC posterior circulation
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outcome, future studies exploring the role of END
biomarkers should also consider haematoma volume and
physiological data collected during the first 24 h after
onset [4, 11, 12].
For patients with ischaemic stroke, the value of
biomarkers as indicators of subclinical penumbral vol-
ume would be best demonstrated by simultaneous MR
or CT perfusion imaging, which are increasingly used to
confirm the presence of tissue that might still be recov-
ered by mechanical thrombectomy [13]. If a strong cor-
relation was found between core:penumbra mis-match
and WBPC, this could indicate a potential role as a
simple screening test to identify patients during the
acute phase of ischaemic stroke who should undergo
advanced imaging, particularly when the symptom onset
time is unclear.
An additional limitation of our study was collection
of NIHSS data from each patient by a single assessor,
but all had completed standard training and were
unaware of the WBPC result. A sensitive definition
for END was applied and although there may be little
clinical benefit derived from identifying patients at
risk of mild deterioration, the observed median
NIHSS increase of 4 points mirrors the most com-
monly employed definition for symptomatic ICH
following thrombolysis.
Conclusions
Early WBPC measurement could be a useful point-of-
care biomarker for identifying patients at risk of END.
However, due to the small size of this mixed cohort and
the sensitive definition used, further research is required
with a larger population which incorporates perfusion
imaging and physiological data to determine how WBPC
relates to stroke pathophysiology, and the added value of
measurement for clinical decision making.
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